254 related articles for article (PubMed ID: 26648749)
1. Optimal management of steroid-dependent ulcerative colitis.
Khan HM; Mehmood F; Khan N
Clin Exp Gastroenterol; 2015; 8():293-302. PubMed ID: 26648749
[TBL] [Abstract][Full Text] [Related]
2. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission.
Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Sociale O; Papa A; De Vitis I; Rapaccini GL; Guidi L
Inflamm Bowel Dis; 2013 Apr; 19(5):1065-72. PubMed ID: 23448790
[TBL] [Abstract][Full Text] [Related]
3. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy options for ulcerative colitis.
Chaparro M; Gisbert JP
Expert Opin Pharmacother; 2016 Jul; 17(10):1339-49. PubMed ID: 27240112
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
Thorlund K; Druyts E; Toor K; Mills EJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
[TBL] [Abstract][Full Text] [Related]
7. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
[TBL] [Abstract][Full Text] [Related]
8. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis.
Church PC; Ho S; Sharma A; Tomalty D; Frost K; Muise A; Walters TD; Griffiths AM
J Crohns Colitis; 2019 Aug; 13(8):982-989. PubMed ID: 30715240
[TBL] [Abstract][Full Text] [Related]
9. Thiopurines Maintenance Therapy in Children With Ulcerative Colitis: A Multicenter Retrospective Study.
Abu Hanna F; Atia O; Yerushalmy Feler A; Shouval D; Weiss B; Mresat H; Magen-Rimon R; Zifman E; Turner D; Rinawi F
J Pediatr Gastroenterol Nutr; 2023 Oct; 77(4):505-511. PubMed ID: 37491713
[TBL] [Abstract][Full Text] [Related]
10. Update on the Use of Biologic Therapy in Ulcerative Colitis.
Aggarwal A; Sabol T; Vaziri H
Curr Treat Options Gastroenterol; 2017 Mar; 15(1):155-167. PubMed ID: 28120279
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
Davis R; McParland P; Dodd S; Storey D; Probert C; Collins P; Skouras T; Steel A; Derbyshire E; Dibb M; Subramanian S
Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):661-667. PubMed ID: 30855421
[TBL] [Abstract][Full Text] [Related]
13. How important is onset of action in ulcerative colitis therapy?
Masson S; Nylander D; Mansfield JC
Drugs; 2005; 65(15):2069-83. PubMed ID: 16225364
[TBL] [Abstract][Full Text] [Related]
14. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Nardone OM; De Vitis I; Papa A; Rapaccini GL; Guidi L
Inflamm Bowel Dis; 2014 Aug; 20(8):1368-74. PubMed ID: 24983979
[TBL] [Abstract][Full Text] [Related]
15. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis.
Nishio M; Ishii Y; Hashimoto Y; Otake H; Ogashiwa T; Tsuda S; Yasuhara H; Saigusa Y; Kimura H; Maeda S; Kunisaki R
Scand J Gastroenterol; 2018; 53(10-11):1236-1244. PubMed ID: 30353757
[TBL] [Abstract][Full Text] [Related]
16. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy.
Mañosa M; García V; Castro L; García-Bosch O; Chaparro M; Barreiro-de Acosta M; Carpio D; Aguas M
J Crohns Colitis; 2011 Oct; 5(5):397-401. PubMed ID: 21939912
[TBL] [Abstract][Full Text] [Related]
18. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
[TBL] [Abstract][Full Text] [Related]
19. Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis.
Pugliese D; Felice C; Landi R; Papa A; Guidi L; Armuzzi A
Drug Healthc Patient Saf; 2016; 8():1-7. PubMed ID: 26893582
[TBL] [Abstract][Full Text] [Related]
20. An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis.
Kawalec P; Pilc A
Arch Med Sci; 2016 Oct; 12(5):1097-1109. PubMed ID: 27695502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
